Travere therapeutics and csl vifor announce swissmedic approval of filspari® (sparsentan) for the treatment of iga nephropathy

San diego, oct. 17, 2024 (globe newswire) -- travere therapeutics, inc., (nasdaq: tvtx) and csl vifor today announced that swissmedic has granted temporary marketing authorization for filspari for the treatment of adults with primary iga nephropathy (igan) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). “filspari targets damage directly in the kidney and offers patients a convenient, once daily, oral, non-immunosuppressive treatment that can provide superior results compared to maximally dosed irbesartan, supporting replacing their rasi,” said eric dube, ph.d.
TVTX Ratings Summary
TVTX Quant Ranking